Senti Biosciences Reports Promising Clinical Results for SENTI-202 in AML Trial
I'm PortAI, I can summarize articles.
Senti Biosciences Inc. announced that its investigational CAR-NK cell therapy, SENTI-202, received RMAT designation from the FDA for treating relapsed or refractory hematologic malignancies, including AML. This follows promising results from a Phase 1 trial, showing a 50% overall response rate and 42% complete remission at the recommended Phase 2 dose. SENTI-202 also received Orphan Drug Designation earlier in June 2025. The data was presented at the ASH Annual Meeting on December 8, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments